Secretome Therapeutics Receives FDA Fast Track Designation for HFpEF Cell Therapy STM-01

Secretome Therapeutics has shared an update. The company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, its neonatal cardiac progenitor cell therapy, for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF), a condition with limited disease‑modifying options. The designation comes as Secretome prepares to initiate a Phase 1 clinical trial.

For investors, Fast Track status is a meaningful regulatory milestone that can shorten development timelines and enhance visibility with regulators through more frequent FDA interactions, the option for rolling Biologics License Application submissions, and potential priority review. While STM-01 remains in early-stage development and clinical and regulatory risks are substantial, the designation validates the seriousness of the target indication and the perceived potential of the therapy, which could improve Secretome Therapeutics’ ability to attract partnerships and financing. If early clinical data are favorable, the company could strengthen its competitive positioning in regenerative cardiology and HFpEF, a large market with significant unmet need, potentially supporting long-term value creation.